Salt Lake City, United States
DiscGenics is a pioneering company in the Biotechnology and Health Care space, established in 2007. With its headquarters in the United States, this clinical stage biopharmaceutical firm is dedicated to transforming the management of chronic back pain through regenerative, cell-based therapies.
The company's mission statement, "REVOLUTIONIZING CARE FOR CHRONIC BACK PAIN", underscores its focus on addressing degenerative diseases of the spine. Its flagship product, IDCT, represents a cutting-edge, homologous, allogeneic injectable cell therapy designed for patients with mild to moderate degenerative disc disease. This innovative approach taps into the cells native to the intervertebral disc to potentially offer significant relief to millions struggling with back pain.
DiscGenics's latest funding was a $50.00M Series C round on August 25, 2020, featuring investors like Mitsubishi UFJ Capital, Medical Incubator Japan, Ci:z Investment, Najeeb Thomas, and CareNet. These investments underscore the strong market confidence and potential growth trajectory of the company in the highly demanding Life Sciences sector.
